Recent scientific findings have raised the fear that young athletes may fare worse after sustaining a sports-related concussion than older athletes.

Vanderbilt’s Vaccine and Treatment Evaluation Unit (VTEU) is one of nine U.S. sites funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to test the effectiveness of a vaccine to protect against the H7N9 bird flu that emerged in China this spring.

Using technology he helped develop, Vanderbilt University scientist Bryan Venters, Ph.D., has shed new light on the “dark matter” of the genome and has begun to explore a possible new approach to treating cancer.

Vanderbilt investigators used an in vivo screen in zebrafish to identify a potential new anti-cancer drug.

New mass spectrometry imaging methods will enable studies of the distribution and identification of membrane proteins directly within tissues.

Therapeutic nanoparticles may offer a powerful new way to image and treat cancer at the same time.

Vanderbilt investigators have combined next-generation sequencing technologies and bioinformatics analyses to screen for genome-wide genetic mutations associated with drug resistance in a series of lung cancer cell lines.